“Assessment of Pressor Effects of Drugs”—A New US FDA Draft Guidance for Industry

被引：0

|

作者：

J. Rick Turner

机构：

来源：

Therapeutic Innovation & Regulatory Science | 2018年 / 52卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：397 / 399

页数：2

相关论文

共 50 条

[1] "Assessment of Pressor Effects of Drugs"A New US FDA Draft Guidance for Industry
Turner, J. Rick
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (04) : 397 - 399
[2] FDA Releases New Draft Guidance on Compounded Drugs
不详
JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (02) : 8N - 8N
[3] Biosimilar draft guidance issue by US FDA
Payne, Thomas
BIOANALYSIS, 2012, 4 (07) : 759 - 759
[4] New FDA Draft Guidance on Immunogenicity
Ashwin Parenky
Heather Myler
Lakshmi Amaravadi
Karoline Bechtold-Peters
Amy Rosenberg
Susan Kirshner
Valerie Quarmby
The AAPS Journal, 2014, 16 : 499 - 503
[5] New FDA Draft Guidance on Immunogenicity
Parenky, Ashwin
Myler, Heather
Amaravadi, Lakshmi
Bechtold-Peters, Karoline
Rosenberg, Amy
Kirshner, Susan
Quarmby, Valerie
AAPS JOURNAL, 2014, 16 (03): : 499 - 503
[6] US FDA publishes draft guidance on clinical pharmacogenomics
不详
BIOANALYSIS, 2011, 3 (07) : 720 - 720
[7] US FDA issues draft guidance on shared REMS for generics
Reactions Weekly, 2017, 1679 (1) : 3 - 3
[8] US FDA issues draft guidance on currently unapproved medicines
Reactions Weekly, 2003, 974 (1) : 3 - 3
[9] Revised US draft guidance for compounded drugs released
Reactions Weekly, 2018, 1733 (1) : 1 - 1
[10] Effectiveness of FDA regulation of drugs that have pressor effects
Blankfield, Robert P.
FUTURE CARDIOLOGY, 2020, 16 (01) : 5 - 8

← 1 2 3 4 5 →